Hypertension Drugs: Market Analysis Essay - Growth Prospects & Trends.

Factors Driving Market Growth of Hypertension Drugs

Discuss About The Market Analysis For Hypertension Drugs Market.

Clonidine has become largely available for prescription as a hypersensitive drug and its use has increased its sales volume in the global market this drug is highly convenient in patients with both minimal and severe hypertension. In comparison with other drugs, this drug has relatively low dosage per day. As a result of various factors such as high urbanization and globalization, people are being adversely affected by a coronary disease, heart complications due to high blood pressure. Across the world, it is estimated that 1.12 individuals suffer from hypertension. Accounting for approximately brings 15 million deaths. High blood pressure causes other diseases like heart failure and visual impairment which makes hypertension drugs to have a high demand in the market especially clonidine drug that is used in this case for treatment.

The rise of people living lifestyle and increased stress levels has had a high prevalence of hypertension globally which in turn results to rise in the demand curve of Clonidine hypertension drug. The older people in the society are most likely to have a maximum risk of suffering high blood pressure. Thus approximately 69% of the people with over 60 years of age suffer from hypertension and hypertension-related diseases (Novac 2013).   Therefore, a rise in the number of old people receiving medical care regarding hypertension will boost the market growth and development during the forecast period. In addition to that, the increase in awareness creation programs and workshops among individuals in terms of instilling knowledge on hypertension and its available clonidine treatment drug options will drive the growth of the global market further. A patent expiration date of major drugs and decreased diagnostic rate and also rise in the number of other available generic drugs could tamper with the market growth rate of Clonidine drug..

Various researches provides an extensive study on the analysis regarding the current and new emerging market trends and dynamics in the existing global market. They detail a unitive analysis of the current market estimations from a range of years which is significant in identifying the prevailing market opportunities available. It projects the future anticipated marketability from 2016-2022 regarding its amount value. It enables marketers to understand clearly on the competitive sector across the global market. Also, an in-depth analysis has modern research strategies involving clinical reports within the existing potential market have been provided. The available dynamic factors aid the marketers to understand the behavior of the market. The Clonidine incremental costs in the market value were 29.09USD and 75. 52$Us.During analyzed variations in the market prices of the drug which is cost effective.

Challenges in the Market

Market Research carried out by analysts at Technavio has indicated that the global hypertension drugs market will have an impressive market value of approximately USD 31 billion by the year 2020. The risk of contracting hypertension increases with age thus the developing old people population will help in potential growth prospects of hypertension drug in the market over given period of time (Siebenhofer et al 2013). Various industry reports discuss factors for example awareness creation that impel the market increase prospects by the year 2020. In 2015 the systemic hypertension drugs like Clonidine segment dominated the drug market focusing on alomst86& of the global market share. Its systemic market is anticipated to reach over USD 27 in the coming years. During 2015 the Americas were accounted for the most massive market for high blood pressure drugs accounting for over 43% market share. The global market of these drugs is largely consolidated because of the availability of less clearly established vendors. Companies are investing heavily in the growth of new drugs for the treatment of hypertension patients. (Siebenhofer et al 2013).

The overall market size of cystic fibrosis therapeutics at international level was approximated at the value of 3.56 billion US dollars in the year 2016. The rising preference of this type of drug comprised of the increasing treatment rate at health facilities is one of the main factors that lead to the expected drive for the high demand for this therapeutics over the anticipated period. (O'Sullivan et al 2013). In addition, the increase in R&D amount of funds by private and government organizations, high number of public initiatives that are started by nonprofit enterprises and also the availability of maximum reimbursement policies and strategies are some of the critical reasons required to propel the market forward. According to research data published by drug foundation, the situations arising due to hereditary diseases is constantly developing. In the U. S, the number of patients grew by approximately 1,600 in 2015 as compared to the year 2010. The increasing growth of a number of patients leads to increased demand for this drug in the market.

Fig 1.1 U.S cystic fibrosis therapeutics market

The rising number of drug components in the pipeline has played a key role in the main factors leading to impel anticipated market growth. Also, the increasing number of clinical trials to widen its patient with disorders base with the existing drug market are one of the drivers of this market analysis (O'Sullivan et al 2013).  The presence of several non-profitable organizations, for example, national Cystic Fibrosis foundation involved in the operations related to CF is significant in accounting for the rising demand. They are investing massive amounts to acquire distinct therapeutics for CF and market research analysis.

Cystic Fibrosis Therapeutics Market

Based on the drug class the market is segmented into mucolytic and CFTR drug modulators. These were launched as the only modulator drug in the market has high revenue with a share of 47.3%.

Areas where demand for topical are high RetP system

Cystic fibrosis therapeutics drugs have high demand in topic Caucasian areas as it affects like 70000 affected patients worldwide.

The Regents engineering transfer programs is on high demand in universities where science and engineering educations for studying the various drugs such as Cystic fibrosis therapeutics. These key areas expand the knowledge on the global market demand of Cystic fibrosis therapeutics drugs as it offers the research on their manufacture and supply to the global market. They end up having high demand for example in countries such as Europewhich is typically anticipated to be the second most key lucrative market with an attractive index of 1.1.

Its international market size is anticipated to reach USD 30.4 billion in the next 7 years as indicated by Grand View research (Gupta et al 2017). Various emerging trends propelling this market is the presence of biologics, rising prospective clinical trials and the increasing aged individuals. The rising availability and awareness created by safe drugs are driven to surge the market growth of rheumatoid arthritis drugs. The growing prevalence of this drug type and availability of novel biosimilar provide high market share for the drug in the market leading to increased health expenditure. New emerging products such as Infliximab biologics are expected to favor the market demand for Rheumatoid Arthritis drug.

The global Clonidine drug market is usually segmented based on the existing therapy type and geography location/areas where the drug is needed most. In terms of the therapy type, the market has various categories including beta blockers, alpha blockers, diuretics and renin inhibitors among other more. In terms of geographic locations, the market is analyzed across several countries such as North America, Europe, and the Pacific (Novac 2013).  The key market players of Clonidine drug include Ranbaxy Laboratories Limited, Pfizer Inc. and Lupine limited. These market players provide a competitive market analysis and profiles of hypertension drugs.

These areas that has high prevalence for the drugs will benefit a lot from the increased market demand. Many people are mostly getting affected by the disease especially the aged people in the given areas. The created awareness is also enabling the drug manufacturing companies to get high demand for the drugs in order to maintain continuous market supply globally. In the market this will create large sales volume of the drugs which in turn is advantageous to the company’s profitability. The companies will use the The Regents engineering transfer programs to identify and, modify and develop new drugs for the in order to maintain the growing competition from other developing companies that manufacture similar drugs and who will control the market share in the global sector. Thus these companies will ensure emergence of new drugs in the market for treatment of the various diseases.

References

Picavet, E., Annemans, L., Cleemput, I., Cassiman, D., & Simoens, S. (2012). Market uptake of orphan drugs–a European analysis. Journal of clinical pharmacy and therapeutics, 37(6), 664-667.

Siebenhofer, A., Jeitler, K., Horvath, K., Berghold, A., Siering, U., & Semlitsch, T. (2013). Long-term effects of weight-reducing drugs in hypertensive patients. Cochrane Database Syst Rev, 3.

O'Sullivan, B. P., Orenstein, D. M., & Milla, C. E. (2013). Pricing for orphan drugs: will the market bear what society cannot?. Jama, 310(13), 1343-1344.

Syed, B. A., & Chaudhari, K. (2013). Smoking cessation drugs market.

Li, W., Joshi, M. D., Singhania, S., Ramsey, K. H., & Murthy, A. K. (2014). Peptide vaccine: progress and challenges. Vaccines, 2(3), 515-536.

Dougla, R. G., & Samant, V. B. (2012). The vaccine industry. Plotkin S, Orenstein Offit P, eds. Vaccines. 6th ed. Saunders Elsevier, 33-43.

Andrieux-Meyer, I., Cohn, J., de Araújo, E. S. A., & Hamid, S. S. (2015). The disparity in market prices for hepatitis C virus direct-acting drugs. The Lancet Global Health, 3(11), e676-e677.

Novac, N. (2013). Challenges and opportunities of drug repositioning. Trends in pharmacological sciences, 34(5), 267-272.